NCT01012011View on ClinicalTrials.gov

Regulatory Post Marketing Surveillance Study on Nexavar®

CompletedOBSERVATIONAL

Enrollment

2,845

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

January 31, 2015

Study Completion Date

August 31, 2015

Conditions

Carcinoma, HepatocellularCarcinoma, Renal Cell

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Daily dose, dosage frequency and duration will be decided by physicians.

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY